Recommendations for the management of comorbidities and complications associated with type 2 diabetes (T2D) comprise a substantial section of new clinical guidelines from the American Association of Clinical Endocrinology (AACE), released in September.
Patient Care® recently asked AACE president Sethu Reddy, MD, MBA, to highlight for primary care clinicians which updates in this comprehensive section may be most likely to affect day-to-day clinical management of their patients with T2D.
In the conversation below Reddy discusses making T2D medication choices based on prominent comorbidities, the role of obesity management in reducing risk for or impact of comorbidities and complications, newer agents approved to treat hypercholesterolemia, and novel agents proving effective against chronic kidney disease.
S Sethu K Reddy, MD, MBA, is the president of the American Association of Clinical Endocrinology and senior assocate dean of clinical research at Central Michigan University (CMU) College of Medicine, in Mount Pleasant, MI. Before joining CMU Reddy worked with the Cleveland Clinic in their endocrinology, diabetes and metabolism department for nearly 30 years.